Achondroplasia, also known as short-limb dwarfism, is associated with neurological symptoms and complications due to narrowing of the skeletal structures surrounding the spinal cord.

Researchers from The University of Osaka have developed a mouse model for achondroplasia. The model identified the importance ...

The first and only approved achondroplasia therapy to provide continuous systemic exposure to CNP over the weekly dosing intervalCommercial ...

Achondroplasia is a bone growth disorder caused by a mutation in the FGFR3 gene, resulting in disproportionate short stature and significant health complications. Infigratinib is an investigational ...

Achondroplasia is a genetic skeletal condition that results in disproportionately short stature and medical complications throughout life. Infigratinib is an orally bioavailable FGFR1–3 selective ...

Achondroplasia is one of the most frequent bone disorders that prevents bone growth especially in the arms and legs, resulting in very severe short stature with average height for males and females ...

An investigational oral medication conferred an increase in annualized height velocity at 1 year among children and ...

Shares in BridgeBio were ticking up today after it revealed data from its phase 3 trial of infigratinib in achondroplasia, ...

BridgeBioBBIO stock surged Thursday after the biotech company unveiled promising results for its most "hotly debated" final-phase asset: a potential treatment for the most common form of dwarfism. The ...